Citations (109)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Roberta Bovenzi, Matteo Conti & Tommaso Schirinzi. (2023) Pharmacotherapy for Sydenham’s chorea: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy 24:11, pages 1317-1329.
Read now
Read now
Stanley N Caroff. (2019) Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatric Disease and Treatment 15, pages 785-794.
Read now
Read now
H. Bashir & J. Jankovic. (2018) Treatment options for chorea. Expert Review of Neurotherapeutics 18:1, pages 51-63.
Read now
Read now
Thomas Müller. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Review of Neurotherapeutics 17:12, pages 1135-1144.
Read now
Read now
Haitham Salem, Teresa Pigott, Xiang Y. Zhang, Cristian P. Zeni & Antonio L. Teixeira. (2017) Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Review of Neurotherapeutics 17:9, pages 883-894.
Read now
Read now
Stanley N. Caroff, E. Cabrina Campbell & Benjamin Carroll. (2017) Pharmacological treatment of tardive dyskinesia: recent developments. Expert Review of Neurotherapeutics 17:9, pages 871-881.
Read now
Read now
Lauren C. Seeberger & Robert A. Hauser. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Opinion on Pharmacotherapy 18:12, pages 1279-1287.
Read now
Read now
Stefano Caproni & Carlo Colosimo. (2017) Movement disorders and cerebrovascular diseases: from pathophysiology to treatment. Expert Review of Neurotherapeutics 17:5, pages 509-519.
Read now
Read now
E. Unti, S. Mazzucchi, G. Palermo, U. Bonuccelli & R. Ceravolo. (2017) Antipsychotic drugs in Huntington’s disease. Expert Review of Neurotherapeutics 17:3, pages 227-237.
Read now
Read now
Joseph Jankovic. (2016) Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opinion on Pharmacotherapy 17:18, pages 2461-2470.
Read now
Read now
Thomas Müller. (2015) Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opinion on Investigational Drugs 24:6, pages 737-742.
Read now
Read now
Stacey K Jankelowitz. (2013) Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatric Disease and Treatment 9, pages 1371-1380.
Read now
Read now
Joohi Jimenez-Shahed & Joseph Jankovic. (2013)
Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opinion on Orphan Drugs 1:5, pages 423-436.
Read now
Read now
Articles from other publishers (96)
Vladlena S. Makeeva, Nadezhda S. Dyrkheeva, Olga I. Lavrik, Suren M. Zakian & Anastasia A. Malakhova. (2023) Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing. International Journal of Molecular Sciences 24:23, pages 16798.
Crossref
Crossref
Xandra García-González, Esther Cubo, Lucía Simón-Vicente, Natividad Mariscal, Raquel Alcaraz, Laura Aguado, Jéssica Rivadeneyra-Posadas, Antonio Sanz-Solas & Miriam Saiz-Rodríguez. (2023) Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives. Journal of Personalized Medicine 13:3, pages 385.
Crossref
Crossref
Christelle Nilles, Gabriel Amorelli, Tamara M. Pringsheim & Davide Martino. (2023) “Unvoluntary” Movement Disorders: Distinguishing between Tics, Akathisia, Restless Legs, and Stereotypies. Seminars in Neurology 43:01, pages 123-146.
Crossref
Crossref
Tomoyoshi Komiyama. (2023) Effects of Genetic Mutation Sites in ADR Genes on Modern Chickens Produced and Domesticated by Artificial Selection. Biology 12:2, pages 169.
Crossref
Crossref
Paolo Tucci, Roberta Lattanzi, Cinzia Severini & Luciano Saso. (2022) Nrf2 Pathway in Huntington’s Disease (HD): What Is Its Role?. International Journal of Molecular Sciences 23:23, pages 15272.
Crossref
Crossref
Sudeepto Saha, Manami Jayati Dey, Salman Khan Promon & Yusha Araf. (2022) Pathogenesis and potential therapeutic application of stem cells transplantation in Huntington’s disease. Regenerative Therapy 21, pages 406-412.
Crossref
Crossref
Carolina Gorodetsky & Alfonso Fasano. (2022) Approach to the Treatment of Pediatric Dystonia. Dystonia 1.
Crossref
Crossref
Magdalena Jastrzębska-Więsek, Anna Wesołowska, Marcin Kołaczkowski, Mark A. Varney, Adrian Newman-Tancredi & RonanY. Depoortere. (2022) The selective 5-HT1A receptor agonist, NLX-112, overcomes tetrabenazine-induced catalepsy and depression-like behavior in the rat. Behavioural Pharmacology 33:5, pages 333-341.
Crossref
Crossref
Qilin Liang, Dongmei Wang, Huixia Zhou, Dachun Chen, Meihong Xiu, Lixia Cui & Xiangyang Zhang. (2022) Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment. Journal of Psychiatric Research 151, pages 181-187.
Crossref
Crossref
Ritam Bandopadhyay, Nainshi Mishra, Ruhi Rana, Gagandeep Kaur, Mohammed M. Ghoneim, Sultan Alshehri, Gulam Mustafa, Javed Ahmad, Nabil. A. Alhakamy & Awanish Mishra. (2022) Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Crossref
Kevin Kyle, Yvette Bordelon, Nagagopal Venna & Jenny Linnoila. (2022) Autoimmune and Paraneoplastic Chorea: A Review of the Literature. Frontiers in Neurology 13.
Crossref
Crossref
Melissa Serranilla & Melanie A. Woodin. (2022) Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington’s Disease. Frontiers in Cellular Neuroscience 15.
Crossref
Crossref
David Myland Kaufman, Howard L. Geyer, Mark J. Milstein & Jillian L. Rosengard. 2022. Kaufman's Clinical Neurology for Psychiatrists. Kaufman's Clinical Neurology for Psychiatrists
412
473
.
F. Schneider, D. Stamler, M. J. Bradbury, P. S. Loupe, M. F. Gordon & L. Rabinovich-Guilatt. (2021) The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers. European Journal of Clinical Pharmacology 78:1, pages 11-18.
Crossref
Crossref
Yijing Bai, Long Niu, Song Li & Weidong Le. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4271
4301
.
Sweta Shah, Marc Marie Dooms, Sofia Amaral-Garcia & Mariana Igoillo-Esteve. (2021) Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders. Frontiers in Pharmacology 12.
Crossref
Crossref
Ayaz Ul Haq, Danish Nabi, Mehtab Alam & Samina A Ullah. (2021) The Spectrum of Movement Disorders in Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis Both in Children and Adults: An Experience From a Single Tertiary Care Center. Cureus.
Crossref
Crossref
Roberta Scalise, Giuseppina Sgandurra, Valentina Menici, Nicola Capodagli, Roberta Di Pietro, Domenico M. Romeo, Francesca Sini, Emanuela Pagliano, Maria Foscan, Giovanni Cioni & Roberta Battini. (2021) A Retrospective Longitudinal Study in a Cohort of Children With Dyskinetic Cerebral Palsy Treated With Tetrabenazine. Frontiers in Neurology 12.
Crossref
Crossref
Michael R. Kilbourn, Erin L. Cole & Peter J.H. Scott. (2021) In vitro binding affinity vs. in vivo site occupancy: A PET study of four diastereomers of dihydrotetrabenazine (DTBZ) in monkey brain. Nuclear Medicine and Biology 92, pages 38-42.
Crossref
Crossref
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
418
450.e15
.
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
401
417.e9
.
Joseph Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn & Jennifer Goldman. 2021. Principles and Practice of Movement Disorders. Principles and Practice of Movement Disorders
371
400.e14
.
S.K. Sahu, P.K. Behera, S. Panda, P. Choudhury & L. Rout. (2020) Developments in chemistry and biological application of cotarnine & its analogs. Tetrahedron 76:50, pages 131663.
Crossref
Crossref
Jen-Hau Yang, Rose E. Presby, Renee A. Rotolo, Taina Quiles, Kevin Okifo, Emma Zorda, Roslyn Holly Fitch, Mercè Correa & John D. Salamone. (2020) The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures. Psychopharmacology 237:9, pages 2845-2854.
Crossref
Crossref
Sayali Chandrashekhar DeolankarPrashant Kumar ModiYashwanth SubbannayyaRavishankar PervajeThottethodi Subrahmanya Keshava Prasad. (2020) Molecular Targets from Traditional Medicines for Neuroprotection in Human Neurodegenerative Diseases. OMICS: A Journal of Integrative Biology 24:7, pages 394-403.
Crossref
Crossref
Christine M. Stahl & Andrew Feigin. (2020) Medical, Surgical, and Genetic Treatment of Huntington Disease. Neurologic Clinics 38:2, pages 367-378.
Crossref
Crossref
Pavel Filip & Marek Baláž. (2020) Oral pharmacotherapy of dystonia. Neurologie pro praxi 21:1, pages 15-18.
Crossref
Crossref
Seung-Mann Paek. (2020) Synthesis of Tetrabenazine and Its Derivatives, Pursuing Efficiency and Selectivity. Molecules 25:5, pages 1175.
Crossref
Crossref
Sanem Yilmaz & Jonathan W. Mink. (2020) Treatment of Chorea in Childhood. Pediatric Neurology 102, pages 10-19.
Crossref
Crossref
Yijing Bai, Long Niu, Song Li & Weidong Le. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
31
.
Christopher Huffman. (2019) Exercise Interventions for the Management of Huntington's Disease. Strength & Conditioning Journal 41:5, pages 62-68.
Crossref
Crossref
Kristen A. Stout, Amy R. Dunn, Carlie Hoffman & Gary W. Miller. (2019) The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance. ACS Chemical Neuroscience 10:9, pages 3927-3938.
Crossref
Crossref
Christian G. Widschwendter & Alex Hofer. (2019) Antipsychotic-induced tardive dyskinesia. Current Opinion in Psychiatry 32:3, pages 179-184.
Crossref
Crossref
Dongjian Chen, Chao Huang & Zhuo Chen. (2019) A review for the pharmacological effect of lycopene in central nervous system disorders. Biomedicine & Pharmacotherapy 111, pages 791-801.
Crossref
Crossref
Patrick A. Lewis & Jennifer E. Spillane. 2019. The Molecular and Clinical Pathology of Neurodegenerative Disease. The Molecular and Clinical Pathology of Neurodegenerative Disease
193
219
.
Rachit Chawla & Akshaya Vachharajani. (2018) Abnormal Movements in an Infant. NeoReviews 19:6, pages e357-e360.
Crossref
Crossref
Antonella Macerollo & Günther Deuschl. (2018) Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis. Journal of the Neurological Sciences 389, pages 55-60.
Crossref
Crossref
Roongroj Bhidayasiri, Onanong Jitkritsadakul, Joseph H. Friedman & Stanley Fahn. (2018) Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences 389, pages 67-75.
Crossref
Crossref
Jonathan M. Meyer. (2018) Future directions in tardive dyskinesia research. Journal of the Neurological Sciences 389, pages 76-80.
Crossref
Crossref
Audrey S. Dickey & Albert R. La Spada. (2017) Therapy development in Huntington disease: From current strategies to emerging opportunities. American Journal of Medical Genetics Part A 176:4, pages 842-861.
Crossref
Crossref
Stanley N Caroff, Saurabh Aggarwal & Charles Yonan. (2018) Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of Comparative Effectiveness Research 7:2, pages 135-148.
Crossref
Crossref
Jan Roth. (2018) The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies. Parkinsonism & Related Disorders 46, pages S75-S79.
Crossref
Crossref
Heather Skor, Evan B. Smith, Gordon Loewen, Christopher F. O’Brien, Dimitri E. Grigoriadis & Haig Bozigian. (2017) Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine. Drugs in R&D 17:3, pages 449-459.
Crossref
Crossref
Dimitri E. Grigoriadis, Evan Smith, Sam R. J. Hoare, Ajay Madan & Haig Bozigian. (2017) Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. Journal of Pharmacology and Experimental Therapeutics 361:3, pages 454-461.
Crossref
Crossref
Rita Miguel, Marcelo D. Mendonça, Raquel Barbosa, Filipa Ladeira, Tânia Lampreia, José Vale & Paulo Bugalho. (2016) Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study. Therapeutic Advances in Neurological Disorders 10:2, pages 81-90.
Crossref
Crossref
David Myland Kaufman, Howard L. Geyer & Mark J. Milstein. 2017. Kaufman's Clinical Neurology for Psychiatrists. Kaufman's Clinical Neurology for Psychiatrists
389
447
.
Emma M. Coppen & Raymund A. C. Roos. (2016) Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease. Drugs 77:1, pages 29-46.
Crossref
Crossref
Sweta Goel & William Ondo. 2017. Movement Disorders Curricula. Movement Disorders Curricula
283
289
.
Stephanie Lessig. 2016. Non‐Parkinsonian Movement Disorders. Non‐Parkinsonian Movement Disorders
131
138
.
Antonio Lucio Teixeira, Leonardo Cruz de Souza, Natalia Pessoa Rocha, Erin Furr-Stimming & Edward C. Lauterbach. (2016) Revisiting the neuropsychiatry of Huntington's disease. Dementia & Neuropsychologia 10:4, pages 261-266.
Crossref
Crossref
Jonathan M. Meyer. (2017) Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrums 21:S1, pages 13-24.
Crossref
Crossref
Stanley N. Caroff & E. Cabrina Campbell. (2016) Drug-Induced Extrapyramidal Syndromes. Psychiatric Clinics of North America 39:3, pages 391-411.
Crossref
Crossref
Mariana Zuccherato Bocato, Fernanda de Lima Moreira, Nayara Cristina Perez de Albuquerque, Cristiane Masetto de Gaitani & Anderson Rodrigo Moraes de Oliveira. (2016) In vitro enantioselective human liver microsomal metabolism and prediction of in vivo pharmacokinetic parameters of tetrabenazine by DLLME-CE. Journal of Pharmaceutical and Biomedical Analysis 128, pages 528-537.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs 76:7, pages 779-787.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 76:7, pages 759-777.
Crossref
Crossref
José Fidel Baizabal-Carvallo & Joseph Jankovic. (2016) Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nature Reviews Neurology 12:3, pages 175-185.
Crossref
Crossref
Mary Ann Thenganatt & Joseph Jankovic. (2016) Recent Advances in Understanding and Managing Tourette Syndrome. F1000Research 5, pages 152.
Crossref
Crossref
Subhashie Wijemanne, Joseph Jankovic & Randolph W. Evans. (2016) Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache: The Journal of Head and Face Pain 56:1, pages 153-161.
Crossref
Crossref
James B. Lohr, Carolyn A. Eidt, Areej Abdulrazzaq Alfaraj & Mounir A. Soliman. (2015) The clinical challenges of akathisia. CNS Spectrums 20:S1, pages 1-16.
Crossref
Crossref
Joseph Jankovic, Susan Bressman, William Dauer & Un Jung Kang. (2015) Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Movement Disorders 30:14, pages 1862-1869.
Crossref
Crossref
Lawrence Lin, Sook Wah Yee, Richard B. Kim & Kathleen M. Giacomini. (2015) SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery 14:8, pages 543-560.
Crossref
Crossref
José Fidel Baizabal-Carvallo, Francisco Cardoso & Joseph Jankovic. (2015) Myorhythmia: Phenomenology, etiology, and treatment. Movement Disorders 30:2, pages 171-179.
Crossref
Crossref
Bruno J. Neves, Rodolpho C. Braga, José C. B. Bezerra, Pedro V. L. Cravo & Carolina H. Andrade. (2015) In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni. PLoS Neglected Tropical Diseases 9:1, pages e3435.
Crossref
Crossref
Neepa Patel & Joseph Jankovic. 2015. Movement Disorders. Movement Disorders
705
711
.
Joseph Jankovic & Raymund A.C. Roos. (2014) Chorea associated with Huntington's disease: To treat or not to treat?. Movement Disorders 29:11, pages 1414-1418.
Crossref
Crossref
Elizabeth A. Skillings, Nigel I. Wood & A. Jennifer Morton. (2014) Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of Huntington's disease. Brain and Behavior 4:5, pages 675-686.
Crossref
Crossref
Ritesh A. Ramdhani & Steven J. Frucht. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
419
441
.
Raja Mehanna & Joseph Jankovic. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
398
418
.
Werner Poewe & Benjamin Matosevic. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
247
267
.
Lindsay Hinkle-Johnston & Joseph M. Ferrara. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
144
171
.
Emilio Fernández-Álvarez & Agathe Roubertie. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
115
130
.
Sarah M. Kranick & Avindra Nath. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
89
98
.
Francisco Cardoso. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
73
88
.
Francesc Valldeoriola & Josep Dalmau. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
39
51
.
Werner Poewe & Joseph Jankovic. 2014. Movement Disorders in Neurologic and Systemic Disease. Movement Disorders in Neurologic and Systemic Disease
31
38
.
Joseph Jankovic. 2014. Manual of Botulinum Toxin Therapy. Manual of Botulinum Toxin Therapy
160
167
.
Neepa Patel, Joseph Jankovic & Mark Hallett. (2014) Sensory aspects of movement disorders. The Lancet Neurology 13:1, pages 100-112.
Crossref
Crossref
C. Williams & M. Leuwer. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
243
253
.
Samuel Frank. (2013) Treatment of Huntington’s Disease. Neurotherapeutics 11:1, pages 153-160.
Crossref
Crossref
Mary Ann Thenganatt & Joseph Jankovic. (2013) Treatment of Dystonia. Neurotherapeutics 11:1, pages 139-152.
Crossref
Crossref
Emilio Fernández-Alvarez. 2014. Chorea. Chorea
335
352
.
José Fidel Baizabal-Carvallo, Cecilia Bonnet & Joseph Jankovic. (2013) Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. Journal of Neural Transmission 120:11, pages 1579-1589.
Crossref
Crossref
Olga Waln & Joseph Jankovic. (2013) Zolpidem improves tardive dyskinesia and akathisia. Movement Disorders 28:12, pages 1748-1749.
Crossref
Crossref
Joseph Jankovic. (2013) Medical treatment of dystonia. Movement Disorders 28:7, pages 1001-1012.
Crossref
Crossref
Marco Bisaglia, Elisa Greggio, Mariano Beltramini & Luigi Bubacco. (2013) Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. The FASEB Journal 27:6, pages 2101-2110.
Crossref
Crossref
Raja Mehanna & Joseph Jankovic. (2013) Movement disorders in cerebrovascular disease. The Lancet Neurology 12:6, pages 597-608.
Crossref
Crossref
Venkata Ramu Derangula, Nageswara Rao Pilli, Siva Kumar Nadavala, Vinayender Adireddy, Jaswanth Kumar Inamadugu & Venkateswarlu Ponneri. (2013) Liquid chromatography–tandem mass spectrometric assay for the determination of tetrabenazine and its active metabolites in human plasma: a pharmacokinetic study. Biomedical Chromatography 27:6, pages 792-801.
Crossref
Crossref
Peter A. LeWitt. (2013) Tardive Dyskinesia Caused by Tetrabenazine. Clinical Neuropharmacology 36:3, pages 92-93.
Crossref
Crossref
José Fidel Baizabal‐Carvallo, Amber Stocco, Eyal Muscal & Joseph Jankovic. (2013)
The spectrum of movement disorders in children with anti‐
NMDA
receptor encephalitis
. Movement Disorders 28:4, pages 543-547.
Crossref
Crossref
Raja Mehanna, Christine Hunter, Anthony Davidson, Joohi Jimenez‐Shahed & Joseph Jankovic. (2012)
Analysis of
CYP2D6
genotype and response to tetrabenazine
. Movement Disorders 28:2, pages 210-215.
Crossref
Crossref
David Myland Kaufman & Mark J. Milstein. 2013. Kaufman's Clinical Neurology for Psychiatrists. Kaufman's Clinical Neurology for Psychiatrists
397
453
.
Joseph Jankovic. (2012) Current concepts in Parkinsonʼs disease and other movement disorders. Current Opinion in Neurology 25:4, pages 429-432.
Crossref
Crossref
Ainhi D. Ha & Victor S.C. Fung. (2012) Huntingtonʼs disease. Current Opinion in Neurology 25:4, pages 491-498.
Crossref
Crossref
Jack J. Chen, William G. Ondo, Khashayar Dashtipour & David M. Swope. (2012) Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature. Clinical Therapeutics 34:7, pages 1487-1504.
Crossref
Crossref
Andrea E. Cavanna, Hugh Rickards, Rhiannon Worrall, Pieter J. Hoekstra, Kerstin J. Plessen & Veit Roessner. (2012) From ipse dixit to evidence-based guidelines: On the optimal management of Tourette syndrome. European Journal of Paediatric Neurology 16:3, pages 310-311.
Crossref
Crossref
Katie Kompoliti & Cynthia L. Comella. 2012. Pathy's Principles and Practice of Geriatric Medicine. Pathy's Principles and Practice of Geriatric Medicine
739
749
.